Curr Health Sci J, vol. 44, no. 3, 2018
Therapy Side Effects in Systemic Lupus Erythematosus
[Case Report]
R. POPA(1), L.A. LAUTARU(2), R. LUCRETIU(3), D.C. RUIU(4), D. CARAGEA(4), M. OLTEANU(4), A.R. MIHAILOVICI(5), C. ENE(1), V. PADUREANU(6), R. PADUREANU(7), V. CIRLIG(8)
(1)PhD student, Department of University of, Medicine and Pharmacy of Craiova, Romania,
(2)Student of Dental Medicine of University of, Medicine and Pharmacy of Craiova, Romania,
(3)Department of Hygiene, Faculty of Nursing and Midwives, University of Medicine and Pharmacy of Craiova, Romania,
(4)Department of Nephrology, Emergency Country Hospital of Craiova, Romania,
(5)Department of Cardiology, Emergency Country Hospital of Craiova, Romania,
(6)Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania,
(7)PhD Student Biochemistry Department, University of Medicine and Pharmacy of Craiova, Romania,
(8)Department o Pharmacology, University of Medicine and Pharmacy of Craiova, Romania
Abstract:
Glucosteroids (GS) are widely used drugs for various inflammatory pathologies (Nephrotic syndrome, Proliferative glomerulonephritis, Extramembrane glomerulonephritis, Nephropathy of the Nodous Poliarterita (PAN), Nephropathy from purple Henoch-Schonlein, lupus nephropathy (LN), Acute adrenal insufficiency Waterhouse-Friederichsen, Chronic adrenal insufficiency Addison, Systemic Lupus Erythematosus (SLE), Polymyositis and dermatomyositis, Chronic granulomatosis, Crohn's disease, Hemorrhagic rectocolitis, Hemolytic anemias, Acute leukemias and chronic lymphocytic leukemia, Hodgkin's lymphoma). Although they are prescribed for their anti-inflammatory and immunosuppressive properties, they also have many side effects, hyperglycemia being one of the most common and representative, which is why these drugs need careful monitoring when administered over the long term. This paper presents the case of a 39 year old patient diagnosed with systemic lupus erythematosus (SLE) with class IV lupus nephropathy (LN) who developed numerous complications due to the pathogenic side effects: diabetes, amenorrhea, recurrent infections, and depression.
Keywords: Corticotherapy, systemic erythematosus lupus, cortico-induced diabetes
Corresponding: Alexandru Radu Mihailovici, Department of Cardiology, Emergency Country Hospital of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania, E-mail: drmihailovici@yahoo.com
DOI 10.12865/CHSJ.44.03.18 - Download PDF Therapy Side Effects in Systemic Lupus Erythematosus PDF

Download contents
Journal archive
- vol. 50 no. 4, 2024
- vol. 50 no. 3, 2024
- vol. 50 no. 2, 2024
- vol. 50 no. 1, 2024
- vol. 49 no. 4, 2023
- vol. 49 no. 3, 2023
- vol. 49 no. 2, 2023
- vol. 49 no. 1, 2023
- vol. 48 no. 4, 2022
- vol. 48 no. 3, 2022
- vol. 48 no. 2, 2022
- vol. 48 no. 1, 2022
- vol. 47 no. 4, 2021
- vol. 47 no. 3, 2021
- vol. 47 no. 2, 2021
- vol. 47 no. 1, 2021
- vol. 46 no. 4, 2020
- vol. 46 no. 3, 2020
- vol. 46 no. 2, 2020
- vol. 46 no. 1, 2020
- vol. 45 no. 4, 2019
- vol. 45 no. 3, 2019
- vol. 45 no. 2, 2019
- vol. 45 no. 1, 2019
- vol. 44 no. 4, 2018
- vol. 44 no. 3, 2018
- vol. 44 no. 2, 2018
- vol. 44 no. 1, 2018
- vol. 43 no. 4, 2017
- vol. 43 no. 3, 2017
- vol. 43 no. 2, 2017
- vol. 43 no. 1, 2017
- vol. 42 no. 4, 2016
- vol. 42 no. 3, 2016
- vol. 42 no. 2, 2016
- vol. 42 no. 1, 2016
- vol. 41 no. 4, 2015
- vol. 41 no. 3, 2015
- vol. 41 no. 2, 2015
- vol. 41 no. 1, 2015
- vol. 40 no. 4, 2014
- vol. 40 no. 3, 2014
- vol. 40 no. 2, 2014
- vol. 40 no. 1, 2014
- vol. 39 no. 4, 2013
- vol. 39 no. 3, 2013
- vol. 39 no. 2, 2013
- vol. 39 no. 1, 2013
- vol. 38 no. 4, 2012
- vol. 38 no. 3, 2012
- vol. 38 no. 2, 2012
- vol. 38 no. 1, 2012
- vol. 37 no. 4, 2011
- vol. 37 no. 3, 2011
- vol. 37 no. 2, 2011
- vol. 37 no. 1, 2011
- vol. 36 no. 4, 2010
- vol. 36 no. 3, 2010
- vol. 36 no. 2, 2010
- vol. 36 no. 1, 2010
- vol. 35 no. 4, 2009
- vol. 35 no. 3, 2009
- vol. 35 no. 2, 2009
- vol. 35 no. 1, 2009